INOVIO PHARMACEUTICALS INC

Inovio stock rises 5 % to $0.84, yet still lags behind biotech peers amid volatile market conditions and no new catalyst.

Inovio’s shares plunged 20% as the FDA review of INO‑3107 looms, while a legal win boosts its IP stance—key insights for investors and rare‑disease advocates.

Inovio (INO) shares climb 1.01% to $1.01, amid a 19.35% monthly drop. Learn how its biotech pipeline and peer movements shape investor outlook.